WO1998028312A1 - Pharmaceutical aminophosphonic acid derivatives - Google Patents
Pharmaceutical aminophosphonic acid derivatives Download PDFInfo
- Publication number
- WO1998028312A1 WO1998028312A1 PCT/GB1997/003479 GB9703479W WO9828312A1 WO 1998028312 A1 WO1998028312 A1 WO 1998028312A1 GB 9703479 W GB9703479 W GB 9703479W WO 9828312 A1 WO9828312 A1 WO 9828312A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- formula
- alkyl
- hydroxy
- pyridyl
- Prior art date
Links
- PTMHPRAIXMAOOB-UHFFFAOYSA-N phosphoramidic acid Chemical class NP(O)(O)=O PTMHPRAIXMAOOB-UHFFFAOYSA-N 0.000 title abstract description 7
- 108010033266 Lipoprotein(a) Proteins 0.000 claims abstract description 6
- 102000057248 Lipoprotein(a) Human genes 0.000 claims abstract 3
- 150000001875 compounds Chemical class 0.000 claims description 65
- 125000000217 alkyl group Chemical group 0.000 claims description 36
- 150000003839 salts Chemical class 0.000 claims description 19
- 125000003545 alkoxy group Chemical group 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 15
- 125000001118 alkylidene group Chemical group 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 108090001030 Lipoproteins Proteins 0.000 claims description 7
- 102000004895 Lipoproteins Human genes 0.000 claims description 7
- 230000003247 decreasing effect Effects 0.000 claims description 7
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- 150000002466 imines Chemical class 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 150000001412 amines Chemical class 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- -1 nitro, hydroxy, hydroxymethyl Chemical group 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- 229910052796 boron Inorganic materials 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 229910052740 iodine Inorganic materials 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- 241000790917 Dioxys <bee> Species 0.000 claims description 3
- 208000007536 Thrombosis Diseases 0.000 claims description 3
- 238000002399 angioplasty Methods 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 208000037803 restenosis Diseases 0.000 claims description 3
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 claims description 2
- 125000004849 alkoxymethyl group Chemical group 0.000 claims description 2
- 125000003282 alkyl amino group Chemical group 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- 229910052751 metal Chemical class 0.000 claims description 2
- 239000002184 metal Chemical class 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 238000006268 reductive amination reaction Methods 0.000 claims description 2
- 125000004665 trialkylsilyl group Chemical class 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 2
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 claims 2
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 claims 1
- CAOXLLPVPMAXOL-UHFFFAOYSA-N [(3-tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-[(3,4-diethylpyridin-2-yl)amino]methyl]phosphonic acid Chemical compound CCC1=C(C(=NC=C1)NC(C2=CC(=C(C3=C2CCCC3)O)C(C)(C)C)P(=O)(O)O)CC CAOXLLPVPMAXOL-UHFFFAOYSA-N 0.000 claims 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 abstract description 3
- 102100040214 Apolipoprotein(a) Human genes 0.000 description 36
- 101710115418 Apolipoprotein(a) Proteins 0.000 description 32
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- 239000000203 mixture Substances 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 9
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 8
- 125000003118 aryl group Chemical group 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- CUYKNJBYIJFRCU-UHFFFAOYSA-N 3-aminopyridine Chemical compound NC1=CC=CN=C1 CUYKNJBYIJFRCU-UHFFFAOYSA-N 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- LXCYSACZTOKNNS-UHFFFAOYSA-N diethoxy(oxo)phosphanium Chemical compound CCO[P+](=O)OCC LXCYSACZTOKNNS-UHFFFAOYSA-N 0.000 description 5
- 210000003494 hepatocyte Anatomy 0.000 description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 4
- 241000282567 Macaca fascicularis Species 0.000 description 4
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 4
- 150000001299 aldehydes Chemical class 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 108010012927 Apoprotein(a) Proteins 0.000 description 2
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000007327 hydrogenolysis reaction Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- AXAFNTSHWBEXFQ-UHFFFAOYSA-N 3-tert-butyl-4-hydroxy-5,5-dimethyl-7,8-dihydro-6h-naphthalene-1-carbaldehyde Chemical compound C1CCC(C)(C)C2=C(O)C(C(C)(C)C)=CC(C=O)=C21 AXAFNTSHWBEXFQ-UHFFFAOYSA-N 0.000 description 1
- RVAKIXIMFKPKJU-UHFFFAOYSA-N 3-tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaphthalene-1-carbaldehyde Chemical compound C1CCCC2=C(O)C(C(C)(C)C)=CC(C=O)=C21 RVAKIXIMFKPKJU-UHFFFAOYSA-N 0.000 description 1
- LRRULYRVDZNOOF-UHFFFAOYSA-N 4-hydroxy-2,3,5-trimethylbenzaldehyde Chemical compound CC1=CC(C=O)=C(C)C(C)=C1O LRRULYRVDZNOOF-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 208000014882 Carotid artery disease Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 101000889990 Homo sapiens Apolipoprotein(a) Proteins 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 208000037876 carotid Atherosclerosis Diseases 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000001030 gas--liquid chromatography Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 208000021156 intermittent vascular claudication Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 208000030613 peripheral artery disease Diseases 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
Definitions
- the present invention relates to novel aminophosphonate derivatives, processes for their preparations, pharmaceutical compositions containing them and their use in therapy, in particular for lowering lipoprotein(a) in plama and in tissues.
- Lipoprotein(a) is a LDL-like lipoprotein where its major lipoprotein, apoB-100 is covalently linked to an unusual glycoprotein, apoprotein(a). Due to its structural similarity to plasminogen. apo(a) interfers with the normal physiological thrombosis- hemostasis process. The structural feature of Lp(a), where the LDL lipoprotein is linked to apo(a), is thought to be responsible for its atherogenic and thrombolytic activities.
- Elevated levels of Lp(a) have been associated with the development of atherosclerosis, coronary heart disease, myocardial infarction, cerebral infarction, restenosis following balloon angioplasty and stroke.
- a recent epidemiologic study has provided the clinical proof of a positive correlation between plasma Lp(a) concentrations and the incidence of heart disease (see for instance: "Elevated Plasma Lipoprotein(a) and Coronary Heart Disease in Men Aged 55 Years and Younger"; A.G. Bostom, L. A. Cupples. J.L. Jenner. J.M. Ordovas. L.J. Seman, P.W.F. Wilson, E.J. Schaefer and W.P. Castelli; Journal of American Medical Association 1996, 276, p. 544-548).
- Lp(a) levels in excess of 20-30 mg/dl run a significantly increased risk of heart attacks and stroke.
- An effective therapy for lowering Lp(a) does not exist at present as potent hypocholesterolemic agents such as the HMGCoA reductase inhibitors do not affect Lp(a).
- potent hypocholesterolemic agents such as the HMGCoA reductase inhibitors do not affect Lp(a).
- the only compound shown to lower Lp(a) was niacin.
- the high doses necessary for activity however entail unacceptable side-effects. There is therefore an unmet therapeutic need for agents that effectively reduce elevated levels of Lp(a).
- X c is H, C(i_4)alkyl, or X ⁇ O and one of the two other substituents X a or
- X D may form an alkylidene dioxy ring having from 1 to 4 carbon atoms;
- R a and R 3 which may be identical or different, are H or C ⁇ . ⁇ alkyl;
- n is zero or 1 ;
- Z is H or a C(j _g)alkyl group;
- m is 0 or an integer from 1 to 5;
- X ⁇ is H, or C ⁇ _8)alkyl, C ⁇ _8)alkoxy or halo; and the pyridyl ring is attached by the ring carbon ⁇ - or ⁇ - to the nitrogen (2- or 3 -pyridyl).
- ⁇ l, X ⁇ which may be the same or different, are H, a straight or branched Cj.g alkyl or C g alkoxy group, OH;
- X ⁇ is H, a Cj_4 alkyl group, X ⁇ O and one of the two other substituents ⁇ l and X ⁇ may form a Cj_4 alkylidene dioxy ring; may form a 5 or 6-membered alkylidene ring optionally substituted with C1.4 alkyl groups or a 5 or 6-membered alkylidenedioxy ring optionally substituted with C ⁇ _4 alkyl groups, X 3 is H, a straight or branched Cj.g alkyl or alkoxy group, OH, F, Cl, Br, I ;
- R1 , R2, which may be the same or different, are H, a straight or branched C1. alkyl group;
- B is CH 2 , CH 2 -CH 2 or CH-CH, n is zero or 1 ;
- Z is H, a straight or branched Cj.g alkyl group; m is 0 or an integer from 1 to 5; ⁇ l, Y ⁇ , Y ⁇ and Y ⁇ , which may be the same or different, are H. a straight or branched C ⁇ . g alkyl or C g alkoxy group, a cyano, trifluoromethyl, nitro, hydroxy, hydroxy methyl, C 1 -C4 alkoxymethyl, amino, C ⁇ .4 alkylamino, C ⁇ .4 dialkylamino group, a halogen atom
- ⁇ l is H, hydroxy, C(i _4)alkyl, for instance methyl or t-butyl, or C ⁇ _3)alkoxy. for instance methoxy.
- X 2 is H, hydroxy, C ⁇ _4)alkyl, for instance methyl or t-butyl, or C ⁇ _3)alkoxy.
- methoxy and ⁇ 4 is hydroxy, C(i_4)alkyl, for instance methyl or t-butyl, or C(i _3)alkoxy, for instance methoxy, or
- X 2 and X ⁇ together form a C4 alkylidene ring optionally substituted, for instance by one or two alkyl groups.
- X ⁇ is hydrogen, C _3)alkyl, for instance methyl or C ⁇ _3)alkoxy, for instance methoxy.
- X ⁇ is hydrogen
- (B) n is a direct bond.
- R ⁇ and R 2 is each a C _3)alkyl group, more preferably, a C 2 or C3 alkyl group, in particular R ⁇ and R 2 is ethyl or isopropyl.
- Z is hydrogen
- ⁇ l to Y ⁇ include alkyl, for instance methyl or t-butyl, methoxy or chloro.
- the pyridyl ring is attached to the ring carbon ⁇ - to the nitrogen (3- or 5- pyridyl).
- salts are well known in the art and include inorganic and organic salts, for instance salts with HC1, H2SO4, oxalic acid, maleic acid, sulfonic acid, etc..
- the present invention provides a compound of formula (I ) or a pharmaceutically acceptable salt thereof for use in therapy, in particular as an Lp(a) lowering agent.
- Elevated plasma and tissue levels of lipoprotein(a) is associated accelerated atherosclerosis, abnormal proliferation smooth muscle cells and increased thrombogenesis and expressed in disease states such as, for instance: coronary heart disease, peripheral artery disease : intermittent claudication, thrombosis, restenosis after angioplasty, extracranial carotid atherosclerosis, stroke and atherosclerosis occuring after heart transplant.
- Compounds of formula (I) may also be useful in treating inflammatory diseases and excessive wound healing.
- the compounds of the present invention will generally be administered in a standard pharmaceutical composition.
- the present invention provides for a pharmaceutical composition comprising a compound of formaula (I) and a pharmaceutically acceptable excipient or carrier.
- Suitable excipients and carriers are well known in the art and will be selected with regard to the intended route of administration and standard pharmaceutical practice.
- the compositions may be administered orally in the form of tablets containing such excipients as starch or lactose, or in capsule, ovules or lozenges either alone or in admixture with excipients, or in the form of elixirs or suspensions containing flavoring or coloring agents.
- parenterally may be injected parenterally, for example, intravenously, intramuscularly or subcutaneously.
- parenteral administration they are best used in the form of a sterile aqueous solution which may contain other substances, for example, enough salts or glucose to make the solution isotonic with blood.
- a sterile aqueous solution which may contain other substances, for example, enough salts or glucose to make the solution isotonic with blood.
- the choice of form for administration as well as effective dosages will vary depending, inter alia, on the condition being treated. The choice of mode of administration and dosage is within the skill of the art.
- the compounds of formula (I) and their pharmaceutically acceptable salts which are active when given orally can be formulated as liquids, for example syrups, suspensions or emulsions or as solids for example, tablets, capsules and lozenges.
- a liquid formulation will generally consist of a suspension or solution of the compound or pharmaceutically acceptable salt in suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suspending agent, preservative, flavoring or coloring agents.
- suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suspending agent, preservative, flavoring or coloring agents.
- a composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid formulations. Examples of such carriers include magnesium stearate, starch, lactose, sucrose and cellulose.
- a composition in the form of a capsule can be prepared using routine encapsulation procedures.
- pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carrier(s), for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.
- suitable pharmaceutical carrier(s) for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.
- Typical parenteral compositions consist of a solution or suspension of the compound or pharmaceutically acceptable salt in a sterile aqueous carrier or parenterally acceptable oil. for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil.
- a typical suppository formulation comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof which is active when administered in this way, with a binding and/or lubricating agent such as polymeric glycols, gelatins or cocoa butter or other low melting vegetable or synthetic waxes or fats.
- the composition is in unit dose form such as a tablet or capsule.
- Each dosage unit for oral administration contains preferably from 1 to 250 mg (and for parenteral administration contains preferably from 0.1 to 25 mg) of a compound of the structure (I) or a pharmaceutically acceptable salt thereof calculated as the free base.
- the compounds of the invention will normally be administered to a subject in a daily dosage regimen.
- a daily dosage regimen for an adult patient this may be, for example, an oral dose of between 1 mg and 500 mg, preferably between 1 mg and 250 mg, or an intravenous, subcutaneous, or intramuscular dose of between 0.1 mg and 100 mg, preferably between 0.1 mg and 25 mg, of the compound of the formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base, the compound being administered 1 to 4 times per day.
- compounds of formula (I) in which Z is hydrogen may be prepared by a process which comprises treating an imine of formula (II) :
- R , R2 are as previously defined; or a trialkyl silyl derivative thereof, preferably the trimethyl silyl phosphite, or a metal thereof, for instance the sodium salt, formed in situ by treatment of the compound of structure (III) with a suitable base, for instance sodium hydride, ethoxide or methoxide.
- a suitable base for instance sodium hydride, ethoxide or methoxide.
- the reaction may be carried out in presence or absence of a catalyst.
- Suitable catalysts incude an amine such as diethylamine or triethylamine.
- the reaction may be carried out in presence or in absence of a solvent.
- Suitable solvents include petroleum ether, benzene, toluene, diethyl ether, tetrahydrofuran, 1,2-dimethoxyethane.
- Suitable reaction temperatures are in the range of 30 to l40°C.
- the imine compound of structure (II) may be obtained by condensing an aldehyde compound of structure (I
- ⁇ , X 2 , ⁇ 3, ⁇ 4 s ⁇ 5 ⁇ ⁇ ⁇ d n are as previously defined ; with a primary amine of structure (V) in which Z, m, Ys Y 2 . Y 3 and Y 4 are as previously described; under imine forming conditions.
- the condensation may be effected with or without a catalyst in a solvent such as ether, tetrahydrofuran, benzene, toluene or ethanol.
- a catalyst include molecular sieve, an acid such as glacial acetic acid, p-toluenesulfonic acid, thionyl chloride, titanium tetrachloride, boron trifluoride etherate, or a base such as potassium carbonate.
- the reaction is suitably carried out in the range of 0°C to the boiling point of the solvent being used. For less reactive amines or aldehydes, the reaction may be usefully carried out in a Dean-Stark apparatus.
- Novel compounds of structure (I) may also be prepared by a process which comprises treating equimolar amounts of an aldehyde of structure (IV) , an amine of structure (V) ; and a dialkyl phosphite of structure (III), in which X 1 , X 2 , X 3 , X 4 , ⁇ 5, B ,n, Z, m, Y 1 . Y 2 , Y 3 ,Y 4 , R!
- R 2 are as previously described, suitably in the presence of p- toluenesulfonic acid as a catalyst, in a hydrocarbon solvent such as petroleum ether, benzene, toluene or xylene, at a temperature between ambient room temperature and the boiling point of the solvent being used, and with concomitant elimination of water, for instance, by using a Dean-Stark apparatus.
- a hydrocarbon solvent such as petroleum ether, benzene, toluene or xylene
- m is an integer from 1 to 5 and ⁇ l, Y 2 , Y 3 and Y 4 are as previously described; under reductive amination condiions.
- Suitable such conditions include carrying out the reaction in the presence of sodium cyanoborohydride in an alcoholic solvent, preferably methanol. at a pH between 3 to 6 and at a temperature between 0°C and 25 °C.
- a compound of formula (VI) may be obtained according to the process previously described for a compound of structure (I) from an aldehyde of formula (IV), an amine of structure (VIII)
- A is a protecting group which can be removed by hydrogenolysis, for instance an ⁇ substituted benzyl or benzyloxycarbonyl and a phosphite of structure (III).
- aminophosphonate ester of formula (I) have a basic centre and can form salts, for instance with inorganic acids such as HC1, H2SO4 and with organic acids such as oxalic acid, maleic acid, sulfonic acids, etc... All these salts are integral part of this invention.
- Compounds of structure (I) are racemates as they have at least one chiral center which is the carbon atom in position alpha to the phosphonate group.
- the compounds of formula ( I) therefore exist in the two enantiomeric forms.
- the racemic mixtures (50% of each enantiomer), the pure enantiomers and other mixtures thereof all form part of the present invention.
- Mixtures of enantiomers, including racemates, may be resolved into its constituent enantiomers according to procedures well known in the art, including for instance, chiral chromatography. Unless otherwise indicated, the physical constants and biological data given for compounds of structure (I) refer to racemates.
- n normal, i is iso, s is secondary and t is tertiary.
- t tertiary.
- 's' is singlet
- 'd' is doublet
- 'dd' is double doublet
- T is triplet
- 'm' is multiplet.
- TsOH is p-toluenesulfonic acid monohydrate. The temperatures were recorded in degrees Celsius and the melting points are not corrected.
- Diethyl phosphite (2.05 g, 14.9 mmol) was added to 2.5 g (7.4 mmol) of the crude imine dissolved in 20 ml THF and the mixture was refluxed for 7 h. A further amount of diethyl phosphite (4.8 g, 35 mmol) was added and the mixture was refluxed overnight (total reaction time : 17 h). The solvent and the excess of diethyl phosphite were evaporated and the residue was purified by column chromatography (Si ⁇ 2, 9/1 CHCl 3 /MeOH) to give 2.25g (64%) of a tan solid.
- the compounds of formula (I) were assayed for lowering the production of Lp(a) in primary cultures of Cynomolgus hepatocytes.
- Assay - Hepatocytes were isolated from livers of adult Cynomolgus monkeys by the two- step collagenase perfusion method according to C. Guguen-Guillouzo and A. Guillouzo "Methods for preparation of adult and fetal hepatocytes" p.1-12 in "Isolated and Cultured Hepatocytes". les editions Inserm Paris and John Libbey Eurotext London (1986).
- the viability of cells was determined by Trypan blue staining. The cells were then seeded at a density from 0.7. 10 5 to 1.10 5 viable cells per cm 2 in tissue culture plates in Williams E tissue culture medium containing 10% fetal calf serum. Cells were incubated for 4-6 hours and 24 hours at 37°C in a CO2 incubator (5% CO2) in the presence of 20 ⁇ M of the test compounds dissolved in ethanol. Four to six wells were used for each compound. Nicotinic acid and steroid hormones were used as references to validate the assay system since they are known to decrease Lp(a) in man. Control cells were incubated in the presence of ethanol only.
- Lp(a) concentration The amount of Lp(a) secreted in culture medium was directly assayed by ELISA using a commercially available kit. Cells were washed and lysed as described by A.L. White et al, Journal of Lipid Research vol 34. p. 509-517, (1993) and the cellular content of Lp(a) was assayed as described above. Changes in Lp(a) concentration in culture medium are given as the percentage of value measured for the control plates at 24h.
- the compounds No. 1 , 2, 3, 4 and 7 tested at 20 ⁇ M were found to decrease the Lp(a) secretion in the range from 19% to 22%.
- Study Protocol Male cynomolgus monkeys weighing between 3 and 7 kg were divided into groups of 3 to 4 animals each. Prior to treatment their plasma Lp(a) levels were followed over a two-month period to ascertain a constant baseline value. The Lp(a) values measured at Day -7 and Day -1 were comparable and served as predose values. Test compounds were given orally in gelatin capsules by gavage at the dose of 25 mg/kg/day for 4 weeks and Lp(a) was measured at weekly intervals (Day 7, 14, 21 and 28). At the end of the dosing period, animals were maintained for a treatment free period of 4 weeks, whereupon their plasma Lp(a) levels returned to pretreatment levels. This control provided proof that the decrease in Lp(a) measured was caused by the pharmacological activity of the test compounds.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Aminophosphonates alpha substituted by phenol groups, of formula (I), have lipoprotein(a) lowering activity.
Description
PHARMACEUTICAL AMINOPHOSPHONIC ACID DERIVATIVES
The present invention relates to novel aminophosphonate derivatives, processes for their preparations, pharmaceutical compositions containing them and their use in therapy, in particular for lowering lipoprotein(a) in plama and in tissues.
Lipoprotein(a) [Lp(a)] is a LDL-like lipoprotein where its major lipoprotein, apoB-100 is covalently linked to an unusual glycoprotein, apoprotein(a). Due to its structural similarity to plasminogen. apo(a) interfers with the normal physiological thrombosis- hemostasis process. The structural feature of Lp(a), where the LDL lipoprotein is linked to apo(a), is thought to be responsible for its atherogenic and thrombolytic activities.
Elevated levels of Lp(a) have been associated with the development of atherosclerosis, coronary heart disease, myocardial infarction, cerebral infarction, restenosis following balloon angioplasty and stroke. A recent epidemiologic study has provided the clinical proof of a positive correlation between plasma Lp(a) concentrations and the incidence of heart disease (see for instance: "Elevated Plasma Lipoprotein(a) and Coronary Heart Disease in Men Aged 55 Years and Younger"; A.G. Bostom, L. A. Cupples. J.L. Jenner. J.M. Ordovas. L.J. Seman, P.W.F. Wilson, E.J. Schaefer and W.P. Castelli; Journal of American Medical Association 1996, 276, p. 544-548).
Patients that have Lp(a) levels in excess of 20-30 mg/dl run a significantly increased risk of heart attacks and stroke. An effective therapy for lowering Lp(a) does not exist at present as potent hypocholesterolemic agents such as the HMGCoA reductase inhibitors do not affect Lp(a). Until recently, the only compound shown to lower Lp(a) was niacin. The high doses necessary for activity however entail unacceptable side-effects. There is therefore an unmet therapeutic need for agents that effectively reduce elevated levels of Lp(a).
International application WO97/02037 (Symphar SA; SmithKline Beecham pic, published 23 January 1997), published after the priority date of the present application, describes a group of aminophosphonates alpha substitued by phenol groups of the formula (A):
in which Xa is H, Cπ _g)alkyl, hydroxy or Cπ . g^alkoxy; X^is Cπ _g)alkyl or
Cπ _8)alkoxy; Xc is H, C(i_4)alkyl, or X^O and one of the two other substituents Xa or
XD may form an alkylidene dioxy ring having from 1 to 4 carbon atoms; Ra and R 3 which may be identical or different, are H or Cπ .^alkyl; B is CH2CH2, CH=CH, or CH2; n is zero or 1 ; Z is H or a C(j _g)alkyl group; m is 0 or an integer from 1 to 5; X^ is H, or Cπ _8)alkyl, Cπ _8)alkoxy or halo; and the pyridyl ring is attached by the ring carbon α- or β- to the nitrogen (2- or 3 -pyridyl). These have Lp(a) lowering activity. Compounds of formula (A) fall within scope of the generic disclosure of EP-A-0 559 079. This is directed towards aminophosphonates alpha substitued by phenol groups which are said to be of use in decreasing plasma cholesterol and blood peroxides. It has now been found that further modification of the substituents on the phenyl ring provides compounds with an improved biological profile.
Accordingly, the present invention provides compounds of formula (I):
in which: χl, X^, which may be the same or different, are H, a straight or branched Cj.g alkyl or C g alkoxy group, OH;
X^ is H, a Cj_4 alkyl group, X^O and one of the two other substituents χl and X^ may form a Cj_4 alkylidene dioxy ring;
may form a 5 or 6-membered alkylidene ring optionally substituted with C1.4 alkyl groups or a 5 or 6-membered alkylidenedioxy ring optionally substituted with Cι _4 alkyl groups,
X3 is H, a straight or branched Cj.g alkyl or alkoxy group, OH, F, Cl, Br, I ;
R1 , R2, which may be the same or different, are H, a straight or branched C1. alkyl group;
B is CH2, CH2-CH2 or CH-CH, n is zero or 1 ;
Z is H, a straight or branched Cj.g alkyl group; m is 0 or an integer from 1 to 5; γl, Y^, Y^ and Y^, which may be the same or different, are H. a straight or branched C\. g alkyl or C g alkoxy group, a cyano, trifluoromethyl, nitro, hydroxy, hydroxy methyl, C 1 -C4 alkoxymethyl, amino, C \ .4 alkylamino, C \ .4 dialkylamino group, a halogen atom
(F, Cl, Br, I); or any two adjacent Y1, Y2, γ3 and Y4 may form an optionally substituted
C 1 _g alkylidene or C 1 _g alkylidenedioxy ring; or a pharmaceutically acceptable salt thereof.
Suitably, χl is H, hydroxy, C(i _4)alkyl, for instance methyl or t-butyl, or Cπ _3)alkoxy. for instance methoxy.
Suitably, X2 is H, hydroxy, Cπ _4)alkyl, for instance methyl or t-butyl, or Cπ _3)alkoxy. for instance methoxy and χ4 is hydroxy, C(i_4)alkyl, for instance methyl or t-butyl, or C(i _3)alkoxy, for instance methoxy, or X2 and X^ together form a C4 alkylidene ring optionally substituted, for instance by one or two alkyl groups.
Suitably, X^ is hydrogen, C _3)alkyl, for instance methyl or Cπ _3)alkoxy, for instance methoxy.
Preferably, X^ is hydrogen.
Preferably, (B)n is a direct bond.
Preferably, R^ and R2 is each a C _3)alkyl group, more preferably, a C2 or C3 alkyl group, in particular R^ and R2 is ethyl or isopropyl.
Preferably, Z is hydrogen.
Representative values for γl to Y^ include alkyl, for instance methyl or t-butyl, methoxy or chloro.
Preferably, the pyridyl ring is attached to the ring carbon β- to the nitrogen (3- or 5- pyridyl).
Pharmaceutically acceptable salts are well known in the art and include inorganic and organic salts, for instance salts with HC1, H2SO4, oxalic acid, maleic acid, sulfonic acid, etc..
Compounds of formula (I) are found to be effective in decreasing Lp(a) production by primary cultures of Cynomolgus monkey hepatocytes. The Lp(a) of these primates is similar in immunologic properties to human Lp(a) and occurs in an almost identical frequency distribution of plasma concentrations (see "Plasma Lipoprotein(a) Concentration is Controlled by Apolipoprotein(a) Protein Size and the Abundance of Hepatic Apo(a) mRNA in a Cynomolgus Monkey Model", N. Azrolan et al, J. Biol. Chem., 266. 13866-13872, 1991). The compounds of formula (I) are thus potentially useful for decreasing Lp(a) in man and thereby providing a therapeutic benefit.
Accordingly, in a further aspect, the present invention provides a compound of formula (I ) or a pharmaceutically acceptable salt thereof for use in therapy, in particular as an Lp(a) lowering agent. Elevated plasma and tissue levels of lipoprotein(a) is associated accelerated atherosclerosis, abnormal proliferation smooth muscle cells and increased thrombogenesis and expressed in disease states such as, for instance: coronary heart disease, peripheral artery disease : intermittent claudication, thrombosis, restenosis after angioplasty, extracranial carotid atherosclerosis, stroke and atherosclerosis occuring after heart transplant. Compounds of formula (I) may also be useful in treating inflammatory diseases and excessive wound healing.
For such therapeutic use, the compounds of the present invention will generally be administered in a standard pharmaceutical composition. Accordingly, in a further aspect, the present invention provides for a pharmaceutical composition comprising a compound of formaula (I) and a pharmaceutically acceptable excipient or carrier. Suitable excipients and carriers are well known in the art and will be selected with regard to the intended route of administration and standard pharmaceutical practice. For example, the compositions may be administered orally in the form of tablets containing such excipients as starch or lactose, or in capsule, ovules or lozenges either alone or in admixture with excipients, or in the form of elixirs or suspensions containing flavoring or coloring agents. They may be injected parenterally, for example, intravenously, intramuscularly or subcutaneously. For parenteral administration, they are best used in the form of a sterile aqueous solution which may contain other substances, for example, enough salts or
glucose to make the solution isotonic with blood. The choice of form for administration as well as effective dosages will vary depending, inter alia, on the condition being treated. The choice of mode of administration and dosage is within the skill of the art.
The compounds of formula (I) and their pharmaceutically acceptable salts which are active when given orally can be formulated as liquids, for example syrups, suspensions or emulsions or as solids for example, tablets, capsules and lozenges. A liquid formulation will generally consist of a suspension or solution of the compound or pharmaceutically acceptable salt in suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suspending agent, preservative, flavoring or coloring agents. A composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid formulations. Examples of such carriers include magnesium stearate, starch, lactose, sucrose and cellulose. A composition in the form of a capsule can be prepared using routine encapsulation procedures. For example, pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carrier(s), for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule. Typical parenteral compositions consist of a solution or suspension of the compound or pharmaceutically acceptable salt in a sterile aqueous carrier or parenterally acceptable oil. for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil. Alternatively, the solution can be lyophilised and then reconstituted with a suitable solvent just prior to administration. A typical suppository formulation comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof which is active when administered in this way, with a binding and/or lubricating agent such as polymeric glycols, gelatins or cocoa butter or other low melting vegetable or synthetic waxes or fats.
Preferably the composition is in unit dose form such as a tablet or capsule. Each dosage unit for oral administration contains preferably from 1 to 250 mg (and for parenteral administration contains preferably from 0.1 to 25 mg) of a compound of the structure (I) or a pharmaceutically acceptable salt thereof calculated as the free base.
The compounds of the invention will normally be administered to a subject in a daily dosage regimen. For an adult patient this may be, for example, an oral dose of between 1 mg and 500 mg, preferably between 1 mg and 250 mg, or an intravenous, subcutaneous, or intramuscular dose of between 0.1 mg and 100 mg, preferably between 0.1 mg and 25
mg, of the compound of the formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base, the compound being administered 1 to 4 times per day.
Compounds of formula (I) may be prepared by processes well known in the art, for instance those previously described in WO 97/02037.
Thus, for instance, compounds of formula (I) in which Z is hydrogen may be prepared by a process which comprises treating an imine of formula (II) :
in which χl, χ2, χ3. χ4? χ5? B? n? m. γl; γ2; γ3^ γ4 are as previously defined: with a dialkyl phosphite of structure (III)
H-P0(0R1)(0R2) (III) in which R , R2 are as previously defined; or a trialkyl silyl derivative thereof, preferably the trimethyl silyl phosphite, or a metal thereof, for instance the sodium salt, formed in situ by treatment of the compound of structure (III) with a suitable base, for instance sodium hydride, ethoxide or methoxide.
The reaction may be carried out in presence or absence of a catalyst. Suitable catalysts incude an amine such as diethylamine or triethylamine. The reaction may be carried out in presence or in absence of a solvent.
Suitable solvents include petroleum ether, benzene, toluene, diethyl ether, tetrahydrofuran, 1,2-dimethoxyethane. Suitable reaction temperatures are in the range of 30 to l40°C.
The imine compound of structure (II) may be obtained by condensing an aldehyde compound of structure (I
in which χ , X2, χ3, χ4 s χ5^ β ^d n are as previously defined ; with a primary amine of structure (V)
in which Z, m, Ys Y2. Y3 and Y4 are as previously described; under imine forming conditions.
Suitably, the condensation may be effected with or without a catalyst in a solvent such as ether, tetrahydrofuran, benzene, toluene or ethanol. Suitable catalysts include molecular sieve, an acid such as glacial acetic acid, p-toluenesulfonic acid, thionyl chloride, titanium tetrachloride, boron trifluoride etherate, or a base such as potassium carbonate. The reaction is suitably carried out in the range of 0°C to the boiling point of the solvent being used. For less reactive amines or aldehydes, the reaction may be usefully carried out in a Dean-Stark apparatus.
Novel compounds of structure (I) may also be prepared by a process which comprises treating equimolar amounts of an aldehyde of structure (IV) , an amine of structure (V) ; and a dialkyl phosphite of structure (III), in which X1, X2, X3, X4 , χ5, B ,n, Z, m, Y1. Y2, Y3 ,Y4 , R! and R2 are as previously described, suitably in the presence of p- toluenesulfonic acid as a catalyst, in a hydrocarbon solvent such as petroleum ether, benzene, toluene or xylene, at a temperature between ambient room temperature and the boiling point of the solvent being used, and with concomitant elimination of water, for instance, by using a Dean-Stark apparatus.
Compounds of formula (I) in which m is not zero may also be prepared by a process which comprises treating a compound of formula (VI): o
in which m is an integer from 1 to 5 and γl, Y2, Y3 and Y4 are as previously described; under reductive amination condiions.
Suitable such conditions include carrying out the reaction in the presence of sodium cyanoborohydride in an alcoholic solvent, preferably methanol. at a pH between 3 to 6 and at a temperature between 0°C and 25 °C.
A compound of formula (VI) may be obtained according to the process previously described for a compound of structure (I) from an aldehyde of formula (IV), an amine of structure (VIII)
A-NH2 (VIII) in which A is a protecting group which can be removed by hydrogenolysis, for instance an α substituted benzyl or benzyloxycarbonyl and a phosphite of structure (III). This forms an intermediate which is then subjected to hydrogenolysis according to standard conditions, to give a compound of formula (VI).
It will be appreciated that the aminophosphonate ester of formula (I) have a basic centre and can form salts, for instance with inorganic acids such as HC1, H2SO4 and with organic acids such as oxalic acid, maleic acid, sulfonic acids, etc... All these salts are integral part of this invention.
Compounds of structure (I) are racemates as they have at least one chiral center which is the carbon atom in position alpha to the phosphonate group. The compounds of formula ( I) therefore exist in the two enantiomeric forms. The racemic mixtures (50% of each enantiomer), the pure enantiomers and other mixtures thereof all form part of the present invention. Mixtures of enantiomers, including racemates, may be resolved into its constituent enantiomers according to procedures well known in the art, including for instance, chiral chromatography. Unless otherwise indicated, the physical constants and biological data given for compounds of structure (I) refer to racemates.
The structure of compounds of formula (I) described in the following Examples was established by their infrared (IR), mass (MS) and nuclear magnetic resonance (NMR) spectra. The purity of the compounds was checked by thin layer, gas liquid or high performance liquid chromatography.
The invention is further described in the following examples which are intended to illustrate the invention without limiting its scope.
The abbreviations used in this application are the following :
In the tables, n is normal, i is iso, s is secondary and t is tertiary. In the description of the NMR spectra, respectively 's' is singlet, 'd' is doublet, 'dd' is double doublet, T is triplet and 'm' is multiplet. TsOH is p-toluenesulfonic acid monohydrate. The temperatures were recorded in degrees Celsius and the melting points are not corrected.
Examples
Example 1 : Diethyl α-(3-tert-butyl-4-hvdroxy-5.6.7.8-tetrahydronaphthylVN-(3- pyridylVaminomethylphosphonate
A mixture of 35g (0.151mol) of 3-tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaphthaldehyde and 14.9 g (0.158mol) of 3-aminopyridine dissolved in 120 ml toluene and a catalytic amount of p-toluenesulfonic acid (ca. 50 mg) contained in a flask connected to a Dean Stark apparatus was refluxed for 4 h. The solution was evaporated to dryness to give a solid which was purified by recrystallisation from a mixture of toluene and ligroin : 35g, mp = 185-186°, IR (KBr) : 1590 cm-1 : CH=N.
Diethyl phosphite (40.3 g, 0.29 mol) was added to 30 g (0.097mol) of the previously described imine dissolved in 100 ml THF and the mixture was refluxed for 16 h. The solvent was evaporated and the residue was purified by column chromatography (Siθ2, 9/1 CH2Cl2/MeOH). Recrystallisation from a mixture of C^C^/AcOEt gave a white solid, mp = l 75- 176°C.
MS (m/e) = 447 : M+ + 1, 309 : M+ - PO3Et2, 57 : t-Bu (100%) NMR (CDC13): δ = 8.0, 7.94, 7.02 and 6.81 (4m, 1H each): aromatic H. 3-ρyridyl 7.29 (d, J = 2Hz, 1H): aromatic H, substituted tetrahydronaphthyl
5.1 (broad, 1H) : OH
4.93 (d x d, 1H, J=7.5 and 23Hz): CH-PO3Et 4.74 (m, 1H): N-H
4.18-3.65 (3m, 4H total): P-O-CH2-CH3 2.9, 2.8, 2.6 and 1.8 (4 m): C-C4H.8 1.34 (s, 9H): t-Bu
1.30 and 1.09: (2t, J-7Hz): P-O-CH2-CH3
Example 2 : Diethyl α-("3-tert-butyl-5.5-dimethyl-4-hydroxy-5.6.7.8-tetrahydronaphthyl)- N- 3-pyridylVaminomethylphosphonate
A mixture of 2.0g (7.7mmol) of 3-tert-butyl-5,5-dimethyl-4-hydroxy-5, 6,7,8- tetrahydronaphthaldehyde and 0.76 g (8.1 mmol) of 3-aminopyridine dissolved in 20 ml toluene and 5 mg of TsOH contained in a flask connected to a Dean Stark apparatus was refluxed for 16 h. The solution was evaporated to dryness to give 2.85g of an oil which was directly used for the next step.
Diethyl phosphite (2.05 g, 14.9 mmol) was added to 2.5 g (7.4 mmol) of the crude imine dissolved in 20 ml THF and the mixture was refluxed for 7 h. A further amount of diethyl phosphite (4.8 g, 35 mmol) was added and the mixture was refluxed overnight (total reaction time : 17 h). The solvent and the excess of diethyl phosphite were evaporated and the residue was purified by column chromatography (Siθ2, 9/1 CHCl3/MeOH) to give 2.25g (64%) of a tan solid. MS (m e) = 475 : M+ - 1, 337 : M+ - PO3Et2, 57 : t-Bu (100%) NMR (CDCI3): δ = 8.14, 7.94, 7.24 and 7.09 (4m, 1H each): aromatic H, 3-pyridyl
7.30 (d, J = 2Hz, 1H): aromatic H, substituted tetrahydronaphthyl 5.5 (broad): OH 5.25 (broad, 1H): N-H 4.94 (d, 1H, J = 22Hz): CH-PO3Et2 4.18-3.5 (4m, 4H total): P-O-CH2-CH3
2.85, 2.76, 1.8 and 1.68 (4 m): C-C4H.6 1.46 and 1.44 (2s, 6H total): c-C H6-(CH3)2 1.34 (s, 9H): t-Bu
1.29 and 1.1 1 : (2t, J=7Hz): P-O-CH2-CH3
Example 3 : Diethyl α-f4-hydroxy-3.5.6-trimethylphenylVN-('3-pyridyl)-amino- methylphosphonate
A mixture of 15.3 g (0.09 mol) of 4-hydroxy-3,5,6-trimethylbenzaldehyde and 8.77 g (0.09 mol) of 3-aminopyridine dissolved in 100 ml toluene and 5 mg of TsOH contained in a flask connected to a Dean Stark apparatus was refluxed for 16 h. The solution was evaporated to dryness to give 20.3 g (83%) of a yellow solid which was directly used for the next step.
Diethyl phosphite (34.5 g, 25 mmol) was added to 20 g (8.3 mmol) of the crude imine dissolved in 150 ml THF and the mixture was refluxed for 22 h. At the end of the refluxing period a precipitate which has formed was collected . Recrystallization from a mixture of ligroine and ethanol gave 20.4 g (65%) of a white solid. MS (m/e) = 378 : M+, 241 : M+ - PO3Et2 NMR (CDCI3): δ = 7.96, 7.92. 7.0 and 6.76 (4m. 1H each): aromatic H. 3-pyridyl 7.06 (d, J = 2Hz, 1H): aromatic H. substituted phenyl 5.5 (broad. 1H) : OH
4.99 and 4.90 (partially overlapped peaks): CH-PO3E12 and N-H 4.18-3.50 (3m, 4H total): P-O-CH2-CH3 2.35, 2.18 and 2.12 (3s,9H total) : aromatic Me
1.31 and 1.09: (2t, 6H. J=7Hz): P-O-CH2-CH3
Further compounds of formula (I) were prepared by following procedures anologous to those described in the foregoing examples. The are included in the following Table 1, along with the preceding examples. The left hand column refers to a 'Compound' rather than the Example number, the same compound numbers being then used in the Biological Data section.
Table 1: Aminophosphonates of formula (I) (where n is 0, XJ and X are H)
Biological Data
The compounds of formula (I) were assayed for lowering the production of Lp(a) in primary cultures of Cynomolgus hepatocytes.
Assay - Hepatocytes were isolated from livers of adult Cynomolgus monkeys by the two- step collagenase perfusion method according to C. Guguen-Guillouzo and A. Guillouzo "Methods for preparation of adult and fetal hepatocytes" p.1-12 in "Isolated and Cultured Hepatocytes". les editions Inserm Paris and John Libbey Eurotext London (1986).
The viability of cells was determined by Trypan blue staining. The cells were then seeded at a density from 0.7. 105 to 1.105 viable cells per cm2 in tissue culture plates in Williams E tissue culture medium containing 10% fetal calf serum. Cells were incubated for 4-6 hours and 24 hours at 37°C in a CO2 incubator (5% CO2) in the presence of 20μM of the test compounds dissolved in ethanol. Four to six wells were used for each compound. Nicotinic acid and steroid hormones were used as references to validate the assay system since they are known to decrease Lp(a) in man. Control cells were incubated in the presence of ethanol only.
Results
Lp(a) concentration - The amount of Lp(a) secreted in culture medium was directly assayed by ELISA using a commercially available kit. Cells were washed and lysed as described by A.L. White et al, Journal of Lipid Research vol 34. p. 509-517, (1993) and the cellular content of Lp(a) was assayed as described above.
Changes in Lp(a) concentration in culture medium are given as the percentage of value measured for the control plates at 24h.
The compounds No. 1 , 2, 3, 4 and 7 tested at 20μM were found to decrease the Lp(a) secretion in the range from 19% to 22%.
In vivo Results
Study Protocol - Male cynomolgus monkeys weighing between 3 and 7 kg were divided into groups of 3 to 4 animals each. Prior to treatment their plasma Lp(a) levels were followed over a two-month period to ascertain a constant baseline value. The Lp(a) values measured at Day -7 and Day -1 were comparable and served as predose values. Test compounds were given orally in gelatin capsules by gavage at the dose of 25 mg/kg/day for 4 weeks and Lp(a) was measured at weekly intervals (Day 7, 14, 21 and 28). At the end of the dosing period, animals were maintained for a treatment free period of 4 weeks, whereupon their plasma Lp(a) levels returned to pretreatment levels. This control provided proof that the decrease in Lp(a) measured was caused by the pharmacological activity of the test compounds.
Results - At Days -7 . -1, 7, 14, 21 and 28, after an overnight fast blood samples were collected on EDTA and Lp(a) was measured by the highly sensitive and specific ELISA test. Results (mean of 3-4 values of each group ) were expressed as %> of predose values.
Selected compounds of formula (I) were tested under the experimental conditions to investigate their pharmacological activity in vivo.
Compounds No 1 and 7 were tested at 25mg/kg/day for 4 weeks and lowered plasma Lp(a) in the range of 35%> to 40%) (value measured at Day 28. % change from predose).
Compound No 2 was tested at 25mg/kg/day for 4 weeks and lowered plasma Lp(a) by 22
% (value measured at Day 14. %> change from predose).
Claims
1. A compound of formula (I)
Cι _8 alkoxy group, OH; X^ is H. a Cj_4 alkyl group, X^O and one of the two other substituents χl and X2 may form a C i .4 alkylidene dioxy ring; X4 is a straight or branched C\.g alkyl or alkoxy group, OH. F. Cl. Br. I; or X4 and X2 may form a 5 or 6-membered alkylidene ring optionally substituted with C]_4 alkyl groups or a 5 or 6-membered alkylidenedioxy ring optionally substituted with Cj_4 alkyl groups, χ5 is H, a straight or branched C\_g alkyl or alkoxy group, OH. F, Cl. Br, I ; RI , R2, which may be the same or different, are H. a straight or branched C\ .β alkyl group;
B is CH , CH2-CH2 or CH=CH. n is zero or 1 ;
Z is H. a straight or branched C j_g alkyl group: m is 0 or an integer from 1 to 5; γl , Y2, Y^ and Y4. which may be the same or different, are H. a straight or branched C \_ g alkyl or C\.g alkoxy group, a cyano. trifluoromethyl, nitro, hydroxy, hydroxymethyl,
C1-C4 alkoxymethyl. amino, Cι _4 alkylamino. Cj_4 dialkylamino group, a halogen atom
(F, Cl. Br, I); or any two adjacent γl, Y2, Y^ and Y4 may form an optionally substituted C\.β alkylidene or C 1.5 alkylidenedioxy ring; or a pharmaceutically acceptable salt thereof.
2. A compound as claimed in claim 1 in which χl is H, hydroxy, Cπ _4)alkyl or Cπ _3)alkoxy.
3. A compound as claimed in claim 1 or 2 in which X2 is H, hydroxy, Cπ _4)alkyl or Cπ _3)alkoxy and X4 is hydroxy, Cπ _4)alkyl. or Cπ _3)alkoxy. or X2 and X4 together form a C4 alkylidene ring optionally substituted, by one or two alkyl groups.
4. A compound as claimed in any one of claims 1 to 3 in which X^ is hydrogen. Cπ „3)alkyl or Cπ _3)alkoxy.
5. A compound as claimed in any one of claims 1 to 4 in which X^ is hydrogen.
6. A compound as claimed in any one of claims 1 to 5 in which(B)n is a direct bond.
7. A compound as claimed in any one of claims 1 to 6 in which R* and R2 is each a Cπ . 3)alkyl group.
8. A compound as claimed in any one of claims 1 to 7 in which Z is hydrogen.
9. A compound as claimed in any one of claims 1 to 8 in which the pyridyl ring is attached to the ring carbon β- to the nitrogen (3- or 5-pyridyl).
10. A compound of structure (I) as defined in claim 1 selected from: diethyl α-(3-tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaphthyl)-N-(3-pyridyl)- aminomethylphosphonate, dimethyl α-(3-tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaphthyl)-N-(3-pyridyl)- aminomethylphosphonate, diisopropyl α-(3-tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaphthyl)-N-(3-pyridyl)- aminomethylphosphonate, diethyl -(3-tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaphthyl)-N-(2-pyridyl)- aminomethylphosphonate, diethyl α-(3-tert-butyl-4-hydroxy-5,6,7,8-tetrahydronaphthyl)-N-(4-pyridyl)- aminomethylphosphonate, diethyl α-(3-tert-butyl-5,5-dimethyl-4-hydroxy-5,6,7,8-tetrahydronaphthyl)-N-(3- pyridyl)-aminomethylphosphonate, and diethyl α-(4-hydroxy-3 ,5 ,6-trimethylphenyl)-N-(3 -pyridyl)-amino-methylphosphonate: or a pharmaceutically acceptable salt thereof.
11. A pharmaceutical composition comprising a compound of formula (I) as defined in claim 1 and a pharmaceutically acceptable excipient thereof.
12. A compound of formula (I) as defined in claim 1, or a pharmaceutically acceptable salt thereof, for use in therapy.
13. The use of a compound of formula (I) as defined in claim 1. or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for use in decreasing plasma and tissue lipoprotein(a) levels.
14 A use of a compound of formula (I) as claimed in claim 13, for the manufacture of a medicament for the treatment of thrombosis by decreasing plasma lipoprotein(a) levels.
15. A use of a compound of formula (I) as claimed in claim 13. for the manufacture of a medicament for the treatment of restenosis following angioplasty by decreasing plasma lipoprotein(a) levels.
16. A use of a compound of formula (I) as claimed in claim 13. for the manufacture of a medicament for the treatment of atherosclerosis by decreasing plasma lipoprotein(a) levels.
17. A method of treating a disease associated with elevated plasma and tissue lipoprotein(a) levels which method comprises administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) as defined in claim 1. or a pharmaceutically acceptable salt thereof.
18. A process for preparing a compound of formula (I) as defined in claim 1 which process comprises:
(a) for compounds of formula (I) in which Z is hydrogen, treating an imine of formula (II) :
in which X1, X2, X3, X4, X5, B, n, m. Y1, Y2, Y3, Y4 are defined in claim 1 ; with a dialkyl phosphite of formula (III):
H-PO(ORJ)(OR2) (III) in which RI and R2 are as defined in claim 1 ; or a trialkyl silyl or metal derivative thereof;
(b) reacting together equimolar amounts of an aldehyde of formula (IV):
1 5
X X
1 2
Y Y
in which Z, m, γl , Y2, Y3 and Y4 are as previously defined: and a dialkyl phosphite of formula (III); or (c) for compounds of formula (I) in which m is not zero, treating a compound of formula
in which χl, X2, X3, X4, X^, B and n are as defined in claim 1. with an aldehyde of formula (VII): 1 Y2
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9626616.8 | 1996-12-20 | ||
GBGB9626616.8A GB9626616D0 (en) | 1996-12-20 | 1996-12-20 | Novel compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998028312A1 true WO1998028312A1 (en) | 1998-07-02 |
Family
ID=10804838
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1997/003479 WO1998028312A1 (en) | 1996-12-20 | 1997-12-18 | Pharmaceutical aminophosphonic acid derivatives |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB9626616D0 (en) |
WO (1) | WO1998028312A1 (en) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002026752A1 (en) * | 2000-09-27 | 2002-04-04 | Ilex Oncology Research S.A. | α-SUBSTITUTED β-AMINOETHYL PHOSPHONATES |
WO2002030904A1 (en) | 2000-10-10 | 2002-04-18 | Smithkline Beecham P.L.C. | Pyridinone derivatives for treatment of atherosclerosis |
WO2003069302A2 (en) * | 2002-02-11 | 2003-08-21 | Ilex Products, Inc. | Alpha-substituted arylalkyl phosphonate derivatives |
US6872711B2 (en) | 2000-10-23 | 2005-03-29 | Ilex Oncology Research S.A. | β-substituted β-aminoethyl phosphonate derivatives |
EP1686119A1 (en) | 2000-02-16 | 2006-08-02 | Smithkline Beecham Plc | Pyrimidine-4-one derivatives as ldl-pla2 inhibitors |
WO2012076435A1 (en) | 2010-12-06 | 2012-06-14 | Glaxo Group Limited | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by lp - pla2 |
WO2013013503A1 (en) | 2011-07-27 | 2013-01-31 | Glaxo Group Limited | 2,3-dihydroimidazo[1,2-c] pyrimidin-5(1h)-one compounds use as lp-pla2 inhibitors |
WO2013014185A1 (en) | 2011-07-27 | 2013-01-31 | Glaxo Group Limited | Bicyclic pyrimidone compounds |
WO2013030374A1 (en) | 2011-09-01 | 2013-03-07 | Glaxo Group Limited | Novel crystal form |
WO2014114248A1 (en) | 2013-01-25 | 2014-07-31 | Glaxosmithkline Intellectual Property Development Limited | Compounds |
WO2014114694A1 (en) | 2013-01-25 | 2014-07-31 | Glaxosmithkline Intellectual Property Development Limited | 2,3-dihydroimidazol[1,2-c]pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (lp-pla2) inhibitors |
WO2014114249A1 (en) | 2013-01-25 | 2014-07-31 | Glaxosmithkline Intellectual Property Development Limited | Bicyclic pyrimidone compounds as inhibitors of lp-pla2 |
WO2016012917A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
WO2016012916A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
WO2021089032A1 (en) | 2019-11-09 | 2021-05-14 | 上海赛默罗生物科技有限公司 | Tricyclic dihydroimidazopyrimidone derivative, preparation method therefor, pharmaceutical composition and use thereof |
WO2022233302A1 (en) | 2021-05-07 | 2022-11-10 | 上海赛默罗生物科技有限公司 | Pyrimidinone derivative and preparation method therefor, pharmaceutical composition, and use |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0559079A1 (en) * | 1992-03-05 | 1993-09-08 | Symphar S.A. | Substituted aminophosphonate derivatives, process for their preparation and pharmaceutical compositions containing them |
EP0703239A1 (en) * | 1994-09-19 | 1996-03-27 | Hoechst Aktiengesellschaft | Aminomethylphosphonic and aminomethylphosphinic acids derivatives and their use in the treatment of degenerative articular diseases |
WO1997002037A1 (en) * | 1995-06-30 | 1997-01-23 | Symphar S.A. | Compounds and pharmaceutical compositions containing them |
-
1996
- 1996-12-20 GB GBGB9626616.8A patent/GB9626616D0/en active Pending
-
1997
- 1997-12-18 WO PCT/GB1997/003479 patent/WO1998028312A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0559079A1 (en) * | 1992-03-05 | 1993-09-08 | Symphar S.A. | Substituted aminophosphonate derivatives, process for their preparation and pharmaceutical compositions containing them |
EP0703239A1 (en) * | 1994-09-19 | 1996-03-27 | Hoechst Aktiengesellschaft | Aminomethylphosphonic and aminomethylphosphinic acids derivatives and their use in the treatment of degenerative articular diseases |
WO1997002037A1 (en) * | 1995-06-30 | 1997-01-23 | Symphar S.A. | Compounds and pharmaceutical compositions containing them |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1686119A1 (en) | 2000-02-16 | 2006-08-02 | Smithkline Beecham Plc | Pyrimidine-4-one derivatives as ldl-pla2 inhibitors |
WO2002026752A1 (en) * | 2000-09-27 | 2002-04-04 | Ilex Oncology Research S.A. | α-SUBSTITUTED β-AMINOETHYL PHOSPHONATES |
US6706698B2 (en) | 2000-09-27 | 2004-03-16 | Ilex Products, Inc. | α-Substituted β-aminoethyl phosphonate derivatives |
WO2002030904A1 (en) | 2000-10-10 | 2002-04-18 | Smithkline Beecham P.L.C. | Pyridinone derivatives for treatment of atherosclerosis |
EP2258688A1 (en) | 2000-10-10 | 2010-12-08 | SmithKline Beecham Limited | Pyridinone derivatives for treatment of atherosclerosis |
US6872711B2 (en) | 2000-10-23 | 2005-03-29 | Ilex Oncology Research S.A. | β-substituted β-aminoethyl phosphonate derivatives |
WO2003069302A2 (en) * | 2002-02-11 | 2003-08-21 | Ilex Products, Inc. | Alpha-substituted arylalkyl phosphonate derivatives |
WO2003069302A3 (en) * | 2002-02-11 | 2003-11-27 | Ilex Products Inc | Alpha-substituted arylalkyl phosphonate derivatives |
WO2012076435A1 (en) | 2010-12-06 | 2012-06-14 | Glaxo Group Limited | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by lp - pla2 |
WO2013013503A1 (en) | 2011-07-27 | 2013-01-31 | Glaxo Group Limited | 2,3-dihydroimidazo[1,2-c] pyrimidin-5(1h)-one compounds use as lp-pla2 inhibitors |
WO2013014185A1 (en) | 2011-07-27 | 2013-01-31 | Glaxo Group Limited | Bicyclic pyrimidone compounds |
WO2013030374A1 (en) | 2011-09-01 | 2013-03-07 | Glaxo Group Limited | Novel crystal form |
WO2014114248A1 (en) | 2013-01-25 | 2014-07-31 | Glaxosmithkline Intellectual Property Development Limited | Compounds |
WO2014114694A1 (en) | 2013-01-25 | 2014-07-31 | Glaxosmithkline Intellectual Property Development Limited | 2,3-dihydroimidazol[1,2-c]pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (lp-pla2) inhibitors |
WO2014114249A1 (en) | 2013-01-25 | 2014-07-31 | Glaxosmithkline Intellectual Property Development Limited | Bicyclic pyrimidone compounds as inhibitors of lp-pla2 |
WO2016012917A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
WO2016012916A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
WO2021089032A1 (en) | 2019-11-09 | 2021-05-14 | 上海赛默罗生物科技有限公司 | Tricyclic dihydroimidazopyrimidone derivative, preparation method therefor, pharmaceutical composition and use thereof |
WO2022233302A1 (en) | 2021-05-07 | 2022-11-10 | 上海赛默罗生物科技有限公司 | Pyrimidinone derivative and preparation method therefor, pharmaceutical composition, and use |
Also Published As
Publication number | Publication date |
---|---|
GB9626616D0 (en) | 1997-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0946572B1 (en) | Pharmaceutical aminophosphonic acid derivatives | |
AU705206B2 (en) | Compounds and pharmaceutical compositions containing them | |
WO1998028312A1 (en) | Pharmaceutical aminophosphonic acid derivatives | |
WO1998028311A1 (en) | Pharmaceutical aminophosphonic acid derivatives | |
MXPA98000189A (en) | Compounds and pharmaceutical compositions that contains them | |
AU2001294792B2 (en) | Alpha-substituted beta-aminoethyl phosphonates | |
US20020111488A1 (en) | Beta-substitued beta-aminoethyl phosphonate derivatives | |
US20030114421A1 (en) | Alpha-substituted beta-aminoethyl phosphonate derivatives | |
CZ219699A3 (en) | Pharmaceutical derivatives of aminophosphonic acid | |
US20050124586A1 (en) | Alpha-substituted arylalkyl phosphonate derivatives | |
US20050124581A1 (en) | Alpha-substituted heteroarylalkyl phosphonate derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase |